Your browser doesn't support javascript.
loading
Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma.
Ohguchi, Hiroto; Park, Paul M C; Wang, Tingjian; Gryder, Berkley E; Ogiya, Daisuke; Kurata, Keiji; Zhang, Xiaofeng; Li, Deyao; Pei, Chengkui; Masuda, Takeshi; Johansson, Catrine; Wimalasena, Virangika K; Kim, Yong; Hino, Shinjiro; Usuki, Shingo; Kawano, Yawara; Samur, Mehmet K; Tai, Yu-Tzu; Munshi, Nikhil C; Matsuoka, Masao; Ohtsuki, Sumio; Nakao, Mitsuyoshi; Minami, Takashi; Lauberth, Shannon; Khan, Javed; Oppermann, Udo; Durbin, Adam D; Anderson, Kenneth C; Hideshima, Teru; Qi, Jun.
Afiliação
  • Ohguchi H; Division of Disease Epigenetics, Institute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan. ohguchi@kumamoto-u.ac.jp Kenneth_anderson@dfci.harvard.edu teru_hideshima@dfci.harvard.edu jun_qi@dfci.harvard.edu.
  • Park PMC; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Wang T; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Gryder BE; Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Ogiya D; Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Case Comprehensive Cancer Center, Cleveland, Ohio.
  • Kurata K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Zhang X; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Li D; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Pei C; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Masuda T; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Johansson C; Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
  • Wimalasena VK; Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.
  • Kim Y; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Hino S; Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Usuki S; Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, Japan.
  • Kawano Y; Liaison Laboratory Research Promotion Center, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, Japan.
  • Samur MK; Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University School of Medicine, Kumamoto, Japan.
  • Tai YT; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Munshi NC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Matsuoka M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Ohtsuki S; Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University School of Medicine, Kumamoto, Japan.
  • Nakao M; Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
  • Minami T; Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, Japan.
  • Lauberth S; Division of Molecular and Vascular Biology, Institute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan.
  • Khan J; Division of Biological Sciences, University of Califonia, San Diego, La Jolla, California.
  • Oppermann U; Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Durbin AD; Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.
  • Anderson KC; Structural Genomics Consortium, University of Oxford, Headington, United Kingdom; Oxford Centre for Translational Myeloma Research, Botnar Research Centre, University of Oxford, Oxford, United Kingdom.
  • Hideshima T; Division of Molecular Oncology, Department of Oncology, and Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Qi J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ohguchi@kumamoto-u.ac.jp Kenneth_anderson@dfci.harvard.edu teru_hideshima@dfci.harvard.edu jun_qi@dfci.harvard.edu.
Blood Cancer Discov ; 2(4): 370-387, 2021 07.
Article em En | MEDLINE | ID: mdl-34258103
ABSTRACT
Lysine demethylase 5A (KDM5A) is a negative regulator of histone H3K4 trimethylation, a histone mark associated with activate gene transcription. We identify that KDM5A interacts with the P-TEFb complex and cooperates with MYC to control MYC targeted genes in multiple myeloma (MM) cells. We develop a cell-permeable and selective KDM5 inhibitor, JQKD82, that increases histone H3K4me3 but paradoxically inhibits downstream MYC-driven transcriptional output in vitro and in vivo. Using genetic ablation together with our inhibitor, we establish that KDM5A supports MYC target gene transcription independent of MYC itself, by supporting TFIIH (CDK7)- and P-TEFb (CDK9)-mediated phosphorylation of RNAPII. These data identify KDM5A as a unique vulnerability in MM functioning through regulation of MYC-target gene transcription, and establish JQKD82 as a tool compound to block KDM5A function as a potential therapeutic strategy for MM.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Lisina / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Lisina / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article